On March 11, 2025, we remember the profound loss and resilience of the people of Japan following the Great East Japan ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

The Fukushima Daiichi nuclear power plant's radiation levels have significantly dropped since the cataclysmic meltdown in ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

Fourteen years after the Fukushima Daiichi meltdown, radiation levels have decreased, but decommissioning efforts remain ...

Daiichi Sankyo meanwhile has started a phase 3 trial of another ADC – patritumab deruxtecan – comparing the drug to chemotherapy as a second-line therapy for EGFR-mutated advanced non-squamous ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

Following its demutualization and IPO in 2010, Daiichi Life Group has transformed from one of Japan’s big four traditional life insurers to a multinational holding company with a multibrand ...

Japan’s top court has found two former company executives not guilty of negligence over the 2011 Fukushima Daiichi nuclear power plant disaster and the subsequent deaths of dozens of elderly residents ...

J.P. Morgan analyst Seiji Wakao maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on March 5 and set a price target ...